Neoplasm of uncertain behavior of right renal pelvis
ICD-10 D41.11 is a billable code used to indicate a diagnosis of neoplasm of uncertain behavior of right renal pelvis.
A neoplasm of uncertain behavior of the right renal pelvis refers to a growth or tumor located in the renal pelvis, which is the area of the kidney where urine collects before moving to the ureter. These neoplasms are characterized by their indeterminate nature, meaning that their potential for malignancy is not clearly defined. Clinically, they may present with symptoms such as hematuria (blood in urine), flank pain, or urinary obstruction. Diagnosis typically involves imaging studies such as ultrasound, CT scans, or MRI, followed by a biopsy to ascertain the nature of the tumor. The uncertain behavior classification indicates that while the tumor may not exhibit aggressive characteristics, there is still a risk of progression to malignancy, necessitating careful monitoring and follow-up. Surveillance strategies may include regular imaging and clinical evaluations to detect any changes in size or behavior of the neoplasm. The management of these neoplasms often requires a multidisciplinary approach, involving urologists, oncologists, and radiologists to ensure appropriate treatment and monitoring.
Detailed imaging reports, biopsy results, and clinical notes on symptoms.
Patients presenting with hematuria or flank pain requiring imaging studies.
Urologists must document the rationale for surveillance and any changes in the neoplasm's behavior.
Comprehensive treatment plans, follow-up notes, and pathology reports.
Patients with a history of renal neoplasms undergoing monitoring for potential malignancy.
Oncologists should ensure clear communication of the neoplasm's behavior and treatment options.
Used when a biopsy is performed to determine the nature of the neoplasm.
Pathology report must be included in the medical record.
Urologists and oncologists should ensure accurate coding based on pathology findings.
It refers to a tumor that does not have a clearly defined potential for malignancy, requiring careful monitoring and follow-up.
Surveillance frequency depends on clinical judgment but typically includes regular imaging and clinical evaluations every 6-12 months.
